Micro Labs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Micro Labs Limited Pharmaceutical Export Portfolio Dataset — 76 Products, $463.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Micro Labs Limited — Pharmaceutical Exporter Profile (2026) | 76 Products, $463.6M Trade | TransData Nexus

Who is Micro Labs Limited? — Company Overview & Market Position

Micro Labs Limited, established in 1973 by the visionary G.C. Surana, is a prominent Indian multinational pharmaceutical company headquartered in Bengaluru, Karnataka. The company operates as a privately held entity, with its Corporate Identification Number (CIN) U24232KA1973PLC002401. As of the fiscal year 2023, Micro Labs reported an estimated revenue of ₹5,300 crore, reflecting its significant presence in the pharmaceutical industry. The workforce comprises over 10,000 employees, underscoring its expansive operations. The official website, microlabsltd.com, provides comprehensive information about the company's products and services.

What Does Micro Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amoxicillin$63.3M 2Potassium$25.1M 3Gabapentin$22.7M 4Losartan$20.5M 5Esomeprazole$20.4M 6Cefixime$19.1M 7Omeprazole$17.2M 8Metformin$16.2M 9Amlodipine$16.0M 10Clarithromycin$15.4M 11Atorvastatin$13.7M 12Telmisartan$8.9M

Micro Labs Limited Therapeutic Categories — 21 Specializations

Micro Labs Limited operates across 21 therapeutic categories, with Antibiotics (21.2%), Cardiovascular (17.3%), Advanced Antibiotics (12.2%) representing the largest segments by export value. The portfolio is well-diversified with the top 5 products representing 33% of exports.

Antibiotics

6 products · 21.2% · $98.1M

Cardiovascular

14 products · 17.3% · $80.0M

Advanced Antibiotics

14 products · 12.2% · $56.7M

Gastrointestinal

6 products · 10.6% · $49.2M

CNS & Psychiatric

4 products · 7.9% · $36.6M

Nutritional Supplements

Product Portfolio — Top 30 by Export Value

Micro Labs Limited exports 76 pharmaceutical products across 21 therapeutic categories. Market leader (#1 exporter) in 6 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$63.3M	1,266	10.4%

All 76 Products

Amoxicillin Potassium Gabapentin Losartan Esomeprazole Cefixime

Key Metrics

Total Trade$463.6M

Products76

Shipments14,326

Categories21

#1 Rankings6

Top 5 Concentration32.8%

Top Categories

Antibiotics21.2%

Cardiovascular17.3%

Advanced Antibiotics12.2%

Last updated: March 28, 2026

Micro Labs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Micro Labs operates 14 state-of-the-art manufacturing plants across India, strategically located in regions such as Sikkim, Goa, Kerala, and Karnataka. These facilities are certified for Good Manufacturing Practices (GMP) and cater to both regulated and emerging markets. The company's manufacturing capabilities span diverse therapeutic areas, including Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, and Neurology.

3Key Leadership

Where Does Micro Labs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Micro Labs has established a robust presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the U.S., the company has a wholly owned subsidiary, Micro Labs USA, Inc., which markets high-quality, affordable generic medicines. These products are manufactured in US FDA-approved facilities in Goa and Bangalore, India, focusing on oral solid tablets and capsules, injections, ophthalmic, and oral solutions. In Europe, Micro Labs has launched its products, adhering to stringent regulatory standards. The company's commitment to quality is further demonstrated by its facilities being accredited by the US FDA and UK MHRA, ensuring compliance with international standards.

2Emerging Markets

Micro Labs has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's acquisition of Swiss Pharma Nigeria Limited (Swipha) in 2016 exemplifies its commitment to penetrating the African market. Additionally, Micro Labs has been actively involved in social responsibility programs in education, healthcare, rural development, and environmental protection, contributing to the development of local communities in these regions.

3Geographic Strategy

Micro Labs has adopted a diversified geographic strategy, establishing a presence in over 50 countries with ground-level operations in 25 countries. This global footprint mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The strategic direction focuses on expanding in existing markets and developing business in new markets like the USA, Eastern Europe, North Africa, and South & Central America, aiming to achieve the status of a "BIG GENERIC COMPANY" in the global pharmaceutical space.

TransData Nexus Research · FDA, EMA, WHO, MHRA, TGA databasesMar 2026

Micro Labs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Micro Labs' commitment to quality is evident in its FDA facility registrations and approved Abbreviated New Drug Applications (ANDAs). The company's facilities in Goa and Bangalore, India, are US FDA-approved, ensuring compliance with stringent regulatory standards. Micro Labs USA, Inc. currently has more than 40 FDA-approved generic products and has filed over twenty-five ANDAs with the FDA at various stages of review, with plans to file ten to fifteen ANDAs annually. This proactive approach underscores the company's dedication to expanding its portfolio in the U.S. market.

2WHO & EU GMP

Micro Labs' manufacturing facilities are certified for Good Manufacturing Practices (GMP) and cater to both regulated and emerging markets. The company's commitment to quality is further demonstrated by its facilities being accredited by the US FDA and UK MHRA, ensuring compliance with international standards. These certifications reflect Micro Labs' adherence to stringent quality standards, facilitating access to global markets.

3CDSCO & Indian Regulatory

Micro Labs operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, ensuring that its manufacturing facilities adhere to the standards set by the Indian regulatory authorities. The company's manufacturing plants are certified for Good Manufacturing Practices (GMP) and cater to both regulated and emerging markets. This adherence to CDSCO guidelines underscores Micro Labs' commitment to maintaining high-quality standards in its operations.

4Recent Regulatory Actions

In July 2022, the Indian Income Tax Department conducted raids on multiple premises of Micro Labs, including offices and residences of promoters across various states. The raids were connected to allegations of tax evasion, unaccounted distribution of freebies to medical professionals, and other promotional practices deemed unethical. The tax authorities estimated the value of these freebies at approximately ₹1,000 crore and claimed the amount of potential tax evasion to be over ₹300 crore. This incident highlights the importance of adhering to ethical business practices and regulatory compliance.

TransData Nexus Research · FDA Orange Book, WHO PQ database, EMA GMP registry, CDSCOMar 2026

Micro Labs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Micro Labs operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. The company's market share and position vary across different segments, with a notable presence in pain management, cardiology, and anti-infectives. The competitive landscape is characterized by the presence of both domestic and international pharmaceutical companies, each vying for market share through product innovation, quality, and distribution networks. Micro Labs' strategic focus on quality, regulatory compliance, and global expansion positions it favorably in this competitive environment.

2Key Differentiators

Micro Labs' key differentiators include its commitment to quality, as evidenced by its state-of-the-art manufacturing facilities and adherence to international regulatory standards. The company's diverse therapeutic portfolio, encompassing areas such as Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, and Neurology, allows it to cater to a wide range of medical needs. Additionally, Micro Labs' global presence and robust distribution network enable it to effectively serve both domestic and international markets. These strengths collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Micro Labs' current strategic direction focuses on expanding its presence in both regulated and emerging markets, with a particular emphasis on the U.S., European, and African markets. The company's acquisition of Swiss Pharma Nigeria Limited (Swipha) in 2016 exemplifies its commitment to penetrating the African market. Looking ahead, Micro Labs aims to achieve the status of a "BIG GENERIC COMPANY" in the global pharmaceutical space, leveraging its strengths in manufacturing, research and development, and distribution. The company's roadmap includes continued investment in discovering, developing, manufacturing, and commercializing innovative medicines, with a focus on digital healthcare trends and commercial excellence.

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Supplier Matching: Micro Labs Limited identified across shipments using name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
3.Market Share: Calculated per product as Micro Labs Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 14,326 individual customs records matching Micro Labs Limited.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

76 Products Tracked

21 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Micro Labs Limited

Micro Labs Limited — Export Portfolio & Destination Treemap

Who is Micro Labs Limited? — Company Overview & Market Position

What Does Micro Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Micro Labs Limited Therapeutic Categories — 21 Specializations

Product Portfolio — Top 30 by Export Value

All 76 Products

Key Metrics

Top Categories

Micro Labs Limited — Corporate Profile & Information

1Corporate Overview

2Manufacturing Facilities

3Key Leadership

Top Export Routes

Related Analysis

Need Detailed Data?

Where Does Micro Labs Limited Export? — Destination Intelligence

1Regulated Markets

2Emerging Markets

3Geographic Strategy

Micro Labs Limited — Manufacturing & Regulatory Profile

1FDA Status

2WHO & EU GMP

3CDSCO & Indian Regulatory

4Recent Regulatory Actions

Micro Labs Limited — Competitive Positioning Among Indian Pharma Exporters

1Competitive Landscape

2Key Differentiators

3Strategic Position

Buyer Due Diligence Brief — Evaluating Micro Labs Limited as a Supplier

1Supplier Assessment

2Certifications to Verify

Frequently Asked Questions — Micro Labs Limited

How many pharmaceutical products does Micro Labs Limited export from India?

What is Micro Labs Limited's total pharmaceutical export value?

In which products is Micro Labs Limited the #1 Indian exporter?

What therapeutic categories does Micro Labs Limited cover?

Get Full Micro Labs Limited Export Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology